Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
06 juil. 2020 06h30 HE
|
Emergent BioSolutions
Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large scale for commercial manufacturing with first two years valued at...
Sorrento Announces Selection of T-VIVA-19™ as Targeted Protein Vaccine Candidate for SARS-CoV-2
01 juil. 2020 12h06 HE
|
Sorrento Therapeutics, Inc.
T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.Novel protein to progress as priority vaccine candidate...
BioNTech to Hold Webcast to Present Early Positive Data from Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
01 juil. 2020 09h28 HE
|
BioNTech SE
MAINZ, Germany, July 01, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) will host a conference call and webcast today, July 1st, 2020 at 11:00 a.m. EDT (5:00 p.m. CET) to discuss...
BioNTech hält Webcast zu ersten positiven Daten aus laufender Phase-1/2-Studie mit mRNA-basiertem SARS-CoV-2-Impfstoffkandidaten ab
01 juil. 2020 09h28 HE
|
BioNTech SE
MAINZ, Deutschland, July 01, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) wird heute, am 1. Juli 2020 um 17.00 MEZ ein Webcast abhalten, um die vorläufigen Daten der...
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
01 juil. 2020 09h01 HE
|
BioNTech SE
In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2 receptor binding domain (RBD)...
Pfizer und BioNTech veröffentlichen erste positive Daten aus laufender Phase-1/2-Studie mit mRNA-basiertem SARS-CoV-2-Impfstoffkandidaten
01 juil. 2020 09h01 HE
|
BioNTech SE
In der laufenden verblindeten, Placebo-kontrollierten Phase-1/2-Studie in den USA wird ein nukleosidmodifizierter messenger-RNA-Impfstoffkandidat (BNT162b1), der für die Rezeptorbindungsdomäne (RBD)...
7 Hills Pharma Highlights Cell Adhesion as Key to Improving Effectiveness of Covid-19 Vaccines and Immuno-Oncology Drugs At BIO Digital 2020 Online Conference
15 juin 2020 10h39 HE
|
7 Hills Pharma
HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical-stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases,...
Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine
15 juin 2020 07h15 HE
|
Treos Bio Corp.
LONDON, June 15, 2020 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical stage biopharma company developing targeted peptide cancer immunotherapies, today said that it has developed and successfully...
7 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12
04 juin 2020 12h58 HE
|
7 Hills Pharma
Company is leveraging its integrin platform technology to improve effectiveness of immunotherapies, including Covid-19 vaccines HOUSTON, June 04, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a...
Amid COVID-19 Vaccine Race, Sabin Vaccine Institute and the Aspen Institute Release Report on Vaccine Hesitancy; A Call to Improve Vaccine Acceptance
02 juin 2020 10h00 HE
|
The Sabin Vaccine Institute
Washington, D.C., June 02, 2020 (GLOBE NEWSWIRE) -- As the COVID-19 vaccine race accelerates, experts recognize that the challenge will not end with the development of a vaccine. The extraordinary...